Maejima Hideki, Watarai Akira, Nakano Toshiaki, Katayama Chieko, Nishiyama Hiromi, Katsuoka Kensei
Department of Dermatology, School of Medicine, Kitasato University, 1-15-1 Kitasato, Sagamihara, Kanagawa, 252-0374, Japan,
Rheumatol Int. 2014 Apr;34(4):571-4. doi: 10.1007/s00296-012-2649-0. Epub 2012 Dec 29.
Methotrexate, a folic acid analogue with anti-proliferative and anti-inflammatory effects, is commonly used to treat patients with severe destructive psoriatic arthritis and has considerable efficacy. Combined anti-tumor necrosis factor and MTX therapy result in less treatment discontinuation due to adverse events. Despite its efficacy, MTX may result in adverse effects including hepatic, pulmonary, and renal toxicity as well as lymphoproliferative disorders and predisposition to infection. We herein report rare adverse effects of MTX treatment, specifically asymptomatic pulmonary tuberculosis, renal cell carcinoma, and lateral uveitis, in three psoriatic arthritis patients treated with MTX. MTX is an important drug for the treatment for psoriatic arthritis patient, but an awareness of the possible adverse effects is needed.
甲氨蝶呤是一种具有抗增殖和抗炎作用的叶酸类似物,常用于治疗重度破坏性银屑病关节炎患者,且疗效显著。联合使用抗肿瘤坏死因子和甲氨蝶呤治疗可减少因不良事件导致的治疗中断。尽管甲氨蝶呤疗效显著,但可能会导致不良反应,包括肝毒性、肺毒性、肾毒性以及淋巴增殖性疾病和易感性感染。我们在此报告了3例接受甲氨蝶呤治疗的银屑病关节炎患者出现的甲氨蝶呤治疗罕见不良反应,具体为无症状肺结核、肾细胞癌和外侧葡萄膜炎。甲氨蝶呤是治疗银屑病关节炎患者的重要药物,但需要了解其可能的不良反应。